Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dual-targeting CAR-NK cells (Beijing Biotech)
- Development stage
- Unknown
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intracranial
01
Overview
Dual-targeting CAR-NK cells (Beijing Biotech) is an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy being developed for the treatment of recurrent or progressive glioblastoma (GBM) and other high-grade gliomas (HGG). This therapy utilizes a biomarker-guided approach where patients' tumors are profiled for the expression of three key antigens: Interleukin-13 receptor subunit alpha-2 (IL13Rα2), Epidermal growth factor receptor (EGFR, including the vIII variant), and B7-H3 (CD276). Based on the individual's antigen profile, a specific dual-targeting CAR-NK construct is selected and administered locoregionally via an intracranial catheter or reservoir. This strategy aims to overcome tumor heterogeneity and prevent antigen escape, a common cause of resistance in single-target CAR therapies. The treatment is typically preceded by lymphodepleting chemotherapy with cyclophosphamide and fludarabine.
- Other names
- IL13Rα2/EGFR/B7-H3 dual-targeting CAR-NK cellsDual-target chimeric antigen receptor natural killer cells
02
Targets
B7-H3EGFRvIII (Epidermal growth factor receptor variant III)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on Dual-targeting CAR-NK cells (Beijing Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dual-targeting CAR-NK cells (Beijing Biotech).